Published in PLoS One on February 10, 2011
Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis (2012) 1.03
Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One (2012) 0.93
Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. Eur J Pharmacol (2013) 0.82
Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue. Sci Rep (2016) 0.79
Tau phosphorylation and μ-calpain activation mediate the dexamethasone-induced inhibition on the insulin-stimulated Akt phosphorylation. PLoS One (2012) 0.78
Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease. PPAR Res (2015) 0.77
Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome. Sci Rep (2017) 0.76
Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation. Front Neurosci (2015) 0.76
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. EXCLI J (2015) 0.75
Toll-interacting protein deficiency promotes neurodegeneration via impeding autophagy completion in high-fat diet-fed ApoE(-/-) mouse model. Brain Behav Immun (2016) 0.75
Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps. Bioessays (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Mitochondrial dysfunction and type 2 diabetes. Science (2005) 10.25
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 7.55
Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A (1992) 5.75
Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci (1991) 5.71
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol (2004) 5.11
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes (2002) 4.97
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest (2004) 4.16
Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology (2007) 4.14
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem (2001) 3.17
Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem (1997) 3.04
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61
Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology (1998) 2.61
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (2004) 2.56
Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A (2004) 2.54
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42
Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci (2000) 2.37
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci (2003) 2.27
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry (2005) 2.21
Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol (2005) 2.20
Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging (2005) 2.15
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A (2005) 2.08
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci (2003) 2.03
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A (2001) 2.00
Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest (1999) 1.85
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82
Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci (2009) 1.79
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging (2009) 1.77
Retracted Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain (2008) 1.60
Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci (2007) 1.58
Diabetes mellitus, dementia, and cognitive function in older persons. J Nutr Health Aging (2006) 1.56
Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci (1998) 1.56
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes (2007) 1.48
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol (2003) 1.44
Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology (2003) 1.44
Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology (2009) 1.39
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology (1997) 1.33
Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28
Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci (2000) 1.27
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging (2008) 1.26
Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis (2008) 1.26
Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol (2000) 1.25
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev (2007) 1.18
Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab (2006) 1.17
Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol (2008) 1.16
PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int (2009) 1.15
Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes (2006) 1.15
Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci (2004) 1.14
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol (2009) 1.14
Abnormalities of glucose metabolism in Alzheimer's disease. Ann N Y Acad Sci (1991) 1.11
Retracted Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes (2009) 1.09
Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem (2004) 1.07
Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis (2010) 1.07
Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem (2002) 1.02
Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Am J Pathol (2010) 0.98
Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes (2005) 0.97
Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep (2009) 0.95
Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology (2010) 0.93
Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J (2005) 0.92
Truncated apoE forms tangle-like structures in a neuronal cell line. Neuroreport (2002) 0.88
Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J (2009) 0.88
Phosphorylation of tau in apolipoprotein E-deficient mice. Neurosci Lett (1995) 0.86
Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem (2006) 0.85
Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. FASEB J (2010) 0.85
Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J Huazhong Univ Sci Technolog Med Sci (2006) 0.81
Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice. Neuroreport (2003) 0.79
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol (2012) 3.31
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry (2009) 3.15
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr (2004) 2.54
The dementias. Lancet (2002) 2.42
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol (2008) 1.74
DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet (2006) 1.73
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet (2012) 1.71
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis (2007) 1.49
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol (2011) 1.35
Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage (2011) 1.34
Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology (2004) 1.32
Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage (2011) 1.30
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28
MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci (2009) 1.28
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing (2003) 1.26
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med (2004) 1.26
AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage (2011) 1.24
Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry (2010) 1.24
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet (2007) 1.16
Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc (2006) 1.15
Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis (2010) 1.12
Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2013) 1.12
Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci (2008) 1.12
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis (2012) 1.11
Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One (2011) 1.10
Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging (2009) 1.09
Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett (2004) 1.09
Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2010) 1.08
p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett (2007) 1.08
A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. Neuroimage (2011) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis (2013) 1.05
Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res (2013) 1.05
A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 1.04
5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics (2008) 1.04
Complement activation as a biomarker for Alzheimer's disease. Immunobiology (2011) 1.04
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04
Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet (2007) 1.03
Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry (2012) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet (2012) 1.02
The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology (2003) 1.01
Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis (2013) 1.01
APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord (2010) 1.00
Education increases reserve against Alzheimer's disease--evidence from structural MRI analysis. Neuroradiology (2012) 0.99
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett (2006) 0.99
Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis (2005) 0.99
Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis (2012) 0.99
Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One (2012) 0.98
Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis (2011) 0.98
Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nat Commun (2013) 0.97
GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci (2006) 0.97
Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Ann Neurol (2006) 0.97
A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis (2009) 0.96
Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry (2007) 0.94
Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet (2007) 0.93
Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. Br J Psychiatry (2011) 0.92
Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging (2012) 0.92
Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92
TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. J Neurochem (2006) 0.91
Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. J Alzheimers Dis (2011) 0.91
No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2011) 0.91
PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Lett (2006) 0.91
Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet (2003) 0.91
Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. J Alzheimers Dis (2010) 0.91
Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Hum Mutat (2005) 0.90
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol (2009) 0.90
Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur J Pharmacol (2002) 0.89
Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol Psychiatry (2007) 0.89
The NEO-FFI is a reliable measure of premorbid personality in patients with probable Alzheimer's disease. Int J Geriatr Psychiatry (2006) 0.89
Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging (2010) 0.88
TAp73alpha induces tau phosphorylation in HEK293a cells via a transcription-dependent mechanism. Neurosci Lett (2006) 0.88